Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 9/20 | 0.41 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | PRKACA | P17612 | 1/20 | 0.41 |
| ▸ | PRKACG | P22612 | 1/20 | 0.41 |
| ▸ | PRKACB | P22694 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | PDE5A | O76074 | 2/20 | 0.39 |
| ▸ | MTHFD2 | P13995 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.38 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.38 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4741309 | 0.86 | KMT2A (0.39) | SMN1; SMN2POLB | |
| SCHEMBL4740381 | 0.83 | MDM2 (0.47) | — | |
| SCHEMBL4741265 | 0.83 | NPC1 (0.50) | SMN1; SMN2POLB | |
| SCHEMBL4740407 | 0.83 | NPC1 (0.50) | SMN1; SMN2POLB | |
| SCHEMBL4739114 | 0.81 | NPC1 (0.51) | SRCSMN1; SMN2 | |
| SCHEMBL4739117 | 0.81 | ALDH1A1 (0.47) | CCR2POLBCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL4738041 | 0.74 | EGLN3 (0.49) | PPARGSMN1; SMN2 | |
| SCHEMBL4741836 | 0.71 | KMT2A (0.44) | — | |
| SCHEMBL4741289 | 0.71 | LMNA (0.43) | — | |
| SCHEMBL4740112 | 0.70 | APLNR (0.53) | POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008089051-A1 | N-SUBSTITUTED GLYCINE DERIVATIVES: PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-24 | — | — | WO | disclosed |
| US-20080171756-A1 | N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2008-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171756-A1 | N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN2, EGLN3 | CCR2 3761/4885ABCB11 2047/4885PPARG 1880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.